Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells

Shundong Cang†, Yuehua Ma†, Jen-wei Chiao2* and Delong Liu2,3*

Abstract
Combination of phenethyl isothiocyanate (PEITC) and paclitaxel (taxol) has been shown to work synergistically to increase apoptosis and cell cycle arrest in breast cancer cells. In this report, we further explored the mechanisms for the synergistic activity of PEITC and taxol in MCF7 and MDA-MB-231 (MB) breast cancer cell lines. By Western blotting analysis, treatment of MCF7 cells with both PEITC and taxol led to a 10.4-fold and 5.96-fold increase in specific acetylation of alpha-tubulin over single agent PEITC and taxol, respectively. This synergistic effect on acetylation of alpha-tubulin was also seen in MB cells. The combination of PEITC and taxol also reduced expressions of cell cycle regulator Cdk1, and anti-apoptotic protein bcl-2, enhanced expression of Bax and cleavage of PARP proteins. In conclusion, this study provided biochemical evidence for the mechanism of synergistic effect between the epigenetic agent PEITC and the chemotherapeutic agent taxol.

Introduction
Epigenetic modification of DNA and histone proteins by methylation and deacetylation plays a key role in carcinogenesis [1-5]. Methyltransferase inhibitors and histone deacetylase (HDAC) inhibitors are novel anti-cancer agents. Two DNA methyltransferase inhibitors, azacitidine and decitabine, and two histone deacetylase inhibitors, vorinostat and romidepsin, have been in clinical use [6-12]. Belinostat was reported to induce durable remission in refractory peripheral T-cell lymphoma [13].

Breast cancer is the most commonly diagnosed cancer and the second leading cause of death among women. Taxanes are a class of major chemotherapeutic agents for breast cancer therapy. Paclitaxel (taxol) is a widely used chemotherapy drug in the treatment of breast cancer and other solid tumors [14-16]. Taxol inhibits microtubule disassembly when it binds to assembled tubulin, making the microtubules locked in polymerized state [17]. Thus the taxol-exposed cells are in cell cycle arrest [18-21]. Another effect of taxol is that it inhibits the anti-apoptosis protein Bcl-2, and induces apoptosis in cancer cells [22]. Even though taxol is a highly effective anti-neoplastic agent, the toxicity of taxol, particularly at a higher dosage, limits its prolonged use in patients [15,23,24]. Further research is being done to increase therapeutic efficacy and minimize toxicity. Radiation and targeted therapy has been used effectively for breast cancer therapy [25-28]. Novel anti-cancer agents with novel mechanisms of actions and new formulations are being actively sought [29-31].

Phenethyl isothiocyanate (PEITC) belongs to the family of isothiocyanates, which are initially found in a wide variety of cruciferous vegetables. Natural ITCs are released when the vegetables are cut or masticated. Phenethyl isothiocyanate (PEITC) regulates epigenetic process. PEITC has been shown to be a HDAC inhibitor in prostate cancer, leukemia, and myeloma cells [32-35]. PEITC was also shown to inhibit leukemia development in mice. PEITC was shown to have dual functions and can induce DNA hypomethylation as well as histone hyperacetylation.
Our group has recently shown that combination of PEITC and taxol has synergistic inhibitory effects on breast cancer cell growth [37]. The combination synergistically increased apoptosis and cell cycle arrest in breast cancer cells. In this report, we further explored the mechanisms for the synergistic activity of PEITC and taxol.

**Materials and methods**

**Chemicals and cell cultures**

As described in previous reports [33-35], PEITC (phenethyl isothiocyanate) was purchased from LKT Labs and dissolved in 70% methanol and 30% deionized water to a stock concentration of 10 mM. Paclitaxel (taxol) powder (Sigma Chemical Co.) was dissolved in DMSO and stored as a stock concentration of 200 nM.

Maintenance and culture of the MCF7 and MDA-MB-231 (MB) cell lines were described in a prior report [37]. Briefly, the cells were seeded at 0.4 × 10^6 per ml and 0.2 × 10^6 per ml, respectively, of PRMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 IU of penicillin/ml and 100 μg of streptomycin/ml, and maintained at 37°C in a humidified atmosphere containing 5% CO₂. At the specified time points, the cells were harvested. Cell number and viability were determined from at least triplicate cultures by the trypan blue exclusion method.

**Western blotting**

MCF and MB cells were treated with PEITC and/or paclitaxel at various concentrations for 48 hours. The cell lysates were used for Western blot analysis as described previously [38,39]. The protein content of the lysates was determined using the BioRad Protein Assay Kit (BioRad, Hercules, CA), with a BSA standard. The antibodies against the following proteins were used for immunoblotting: PARP-1, BCL-2, Bax, Cdk-1, Cyclin B1, α-tubulin, β-tubulin, β-actin, acetyl-α-tubulin, HDAC6, acetyl-H3, and Acetyl-H4 [34,35,40]. Secondary antibodies were chosen according to the primary antibodies used (goat anti-rabbit or anti-mouse IgG antibody linked to HRP, Santa Cruz). The proteins were visualized through the ECL system. The protein was quantified using the β-actin protein as the loading control.

**Confocal immunofluorescence**

Immunostaining of cells for confocal immunofluorescence microscopy was done according to the published methods [35]. Briefly the MCF and MB cells grown on chamber slides were treated for 48 hours without or with PEITC, the cells were then fixed, permeabilized, blocked in BSA and incubated with a mouse anti-acetyl-α-tubulin (Sigma-Aldrich) for 1 h. A fluorescin-conjugated goat anti-mouse IgG was used as secondary antibody. The DNA was counterstained with propidium iodide (PI) to visualize the nuclei of the cells. Images were captured using an MRC 1024 ES confocal laser scanning microscopy system.

**Results**

**PEITC and taxol increased acetylation of alpha-tubulin in breast cancer cells**

Alpha-tubulin has been shown to be acetylated by HDAC6 [41]. When the cells were treated with the combination of PEITC and taxol, the acetylation of alpha-tubulin was significantly increased in both MCF and MB cells in comparison with that in single agent treated cells (Figure 1). When the acetylation level was corrected for the amount of total alpha-tubulin present in the specimen, there was a 16% and 28% respective increase in the specific acetylation level (SAL) of acetylated alpha-tubulin (acetyl-alpha-tubulin per unit of total alpha-tubulin) in MCF cells treated with PEITC or taxol alone (Figure 1). There was a 167% increase in SAL in MCF cells treated with both PEITC and taxol. Therefore, the combination led to a 10.4-fold and 5.96-fold increase in SAL over single agent PEITC and taxol, respectively. This synergistic effect on acetylation of alpha-tubulin was also seen in MB cells (Figure 1). Interestingly, taxol alone also enhanced acetylation of alpha-tubulin in both cell lines. The combination also decreased expression of beta-tubulin more than each agent alone.

To directly visualize the activity of PEITC on breast cancer cells in live cell culture, we next studied the level and distribution of acetylated alpha-tubulin by immunostaining. The cells were visualized with confocal fluorescence microscopy. The cytoplasmic level of acetylated alpha-tubulin clearly increased in both MCF and MB cells after treatment with 5 μM of PEITC for 48 hours, which can be directly visualized under confocal fluorescence microscope (Figure 2).

**Effect of combination of PEITC and taxol on cyclin B1 and CDK1 expression**

Cyclin B1 and CDK1 are major cell cycle regulatory proteins for the G2 to M phase progression [42]. To explore the involvement of the major cell cycle regulatory proteins, the level of cyclin B1 and CDK1 expression was studied. Their expressions were characterized with Western blotting. When compared with single agent PEITC and taxol, the combination of both agents reduced the expression of CDK1 more significantly than either agent alone (Figure 3). In the mean time, the cyclin B1 expression was minimally decreased, indicating a less significant effect from the treatment.

**Effect of combination of PEITC and taxol on Bax and Bcl-2 expression**

Bax and Bcl-2 have opposing effects on apoptosis. Bax promotes apoptosis while Bcl-2 is an anti-apoptosis...
protein. The levels of the two proteins in the breast cancer cell lines were examined through Western blotting analysis. When compared with single agent PEITC and taxol, the combination of both agents reduced Bcl-2 expression and increased Bax expression more than either agent alone (Figure 4).

**Effect of combination of PEITC and taxol on PARP cleavage**

PARP proteins are important downstream components of the apoptosis pathways. Cell cycle arrest usually triggers the apoptosis machinery which leads to cellular apoptosis and cell death. The PARP protein cleavage in MCF and MB cells was examined. When compared with single agent PEITC and taxol, the combination of both agents increased the PARP-1 cleavage (thus an increase in the degradation products as described [43]) more than either agent alone in both cell lines (Figure 4).

**Discussion**

It has been shown that tubulin acetylation primarily occurs on assembled microtubules [44]. PEITC has been previously found to directly bind to alpha- and beta-tubulins, thus inhibiting microtubule polymerization in prostate cancer cells [45]. In this study, PEITC was shown, for the first time, to induce hyperacetylation of alpha-tubulin in two different breast cancer cell lines. It is possible that PEITC can inhibit the synthesis of alpha-
tubulin deacetylase HDAC6 [41] (data not shown). This may help to explain the previous findings that some HDAC inhibitors, such as TSA but not butyric acid, can cause alpha-tubulin hyperacetylation [46]. This study also provided evidence to illustrate the possible mechanisms for the synergistic anti-growth effect of PEITC and taxol to be due to hyperacetylation of alpha-tubulin. This synergism is best explained by the fact that taxol enhances tubulin acetylation by inhibiting depolymerization of microtubules and thus leads to availability of more substrates for acetylases, whereas PEITC decreases tubulin deacetylation.

This study also showed that the combination of PEITC and taxol enhanced apoptosis by decreasing bcl-2 expression and by increasing BAX expression as well as degradation of PARP. The combination of the two agents also reduced CDK1 expression. These biochemical data provided the foundation of the mechanisms for the synergistic effects of the two agents on apoptosis and cell cycle arrest. The similar mechanism was also found to be responsible for PEITC inhibition of prostate cancer cells [32,35,47-49]. Further study of this effect on prostate cancer cells are ongoing in our laboratory.

Our lab and others have shown that PEITC has little toxic effects on normal cells [35,38,50]. However, taxol has significant toxicity at higher dosage and after prolonged use. We therefore hypothesize that by combining PEITC and taxol, it is possible to significantly reduce toxicity in vivo by reducing the dosage of taxol needed while maintaining clinical efficacy for breast cancer and possibly other solid tumors. This hypothesis will be tested first in mouse model carrying breast cancer xenografts.

The HDAC inhibitor vorinostat has been shown to up-regulate estrogen receptors and make breast cancer cells more sensitive to tamoxifen [51]. HDAC inhibitor was found to redirect the response of breast cancers cells to tamoxifen from cell cycle arrest to apoptosis [52]. Since PEITC is a HDAC inhibitor as well as a tubulin-targeting agent, it would be worthwhile to test the combination of PEITC and tamoxifen for therapy of hormone-refractory breast cancer.

Conclusion
This study provided biochemical evidence for the mechanism of synergistic effect between the epigenetic agent
PEITC and the chemotherapeutic agent taxol. This novel strategy deserves further study in vivo in animal models and may provide a new and enhanced treatment option for breast cancer patients.

Competing interests
The authors have no relevant competing interests.

Authors’ contributions
All authors have contributed to data preparation, drafting and revising the manuscripts. All authors have read and approved the final manuscript.

Acknowledgment
This study was partly supported by New York Medical College Blood Diseases Fund (DL).

Author details
1Department of Oncology, Henan Province People’s Hospital, Zhengzhou University, Zhengzhou, China. 2Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA. 3Institute of Hematology, Henan Tumor Hospital, Zhengzhou University, Zhengzhou, China.

Received: 15 December 2013 Accepted: 3 February 2014 Published: 5 February 2014

References
1. Wolfe AP, Matzke MA: Epigenetics: regulation through repression. Science 1999, 286(5439):481–486.
2. Workman JL, Kingston RE: Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 1998, 67:545–579.
3. Ula K, Kurumizaka H, Dmirtov S, Almounzi G, Wolfe AP: Histone acetylation: influence on transcription, nucleosome mobility and positioning, and linker histone-dependent transcriptional repression. EMBO J 1997, 16(8):2096–2107.
4. Bird AP, Wolfe AP: Methylation-induced repression—belts, braces, and chromatin. Cell 1999, 95(5):451–464.
5. Gutierrez S, Romero-Oliva F: Epigenetic changes: a common theme in acute myelogenous leukemia. J Hematol Oncol 2013, 6:157.
6. Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet JP, Kossenskov AV, Wilkerson J, Showe LC, Gottesman MM et al: MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with a MEK inhibitor. Blood 2013, 121(20):4115–4125.
7. Sherman EJ, Su YB, Lyall A, Schoder H, Fury MG, Ghossein RA, Haque S, Lisa D, Shaha AR, Tuttle RM, et al: Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory metastatic breast cancer. J Natl Cancer Inst 2013, 105:1192–1200.
8. van der Helm L, Scheepers E, Veeger N, Daenens S, Mulder A, van den Berg E, Veltenga E, Huls G: Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hematol Oncol 2013, 6:129.
9. Gojo I, Tan M, Fang HB, Sadowska M, Lapidos R, Baer MR, Carrier F, Beumer JH, Anyang BN, Silvestrini RK et al: Translational phase I trial of vorinostat (Suberoylanilide Hydroxamic Acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res 2013, 19(7):1838–1851.
10. Xu S, De Veirman K, Evans H, Santini GC, Vande Broek I, Lelleu X, De Becker A, Van Camp B, Croucher P, Vanderkerken K et al: Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo. Acta Pharmacol Sin 2013, 34(5):699–709.

Cang et al. Experimental Hematology & Oncology 2014, 3:5 Page 5 of 6
http://www.ehoonline.org/content/3/1/5

11. Fianchi L, Criscuolo M, Lunghi M, Gaidano G, Breccia M, Levis A, Finelli C, Santini V, Musto P, Oliva E, et al: Outcome of therapy-related myeloid neoplasms treated with azacitidine. J Hematol Oncol 2012, 5(1):44.
12. Reimer P, Chawla S: Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma. J Hematol Oncol 2013, 6:159.
13. Holmes FA, Walters RS, Therault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991, 83(24):1797–1805.
14. Brown T, Havin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J, Von HD: A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991, 9(7):1261–1267.
15. McGuire WP, Rovinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989, 111(4):273–279.
16. Jordan MA, Kamath K: How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 2007, 7(8):730–742.
17. Fujis DA, Johnson RK: Cytogenic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep 1978, 62(8):1219–1222.
18. Schiff PB, Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980, 77(3):1561–1565.
19. Schiff PB, Horwitz SB: Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated protein 2. Zeits. Biochem 1981, 201(13):347–352.
20. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277(5698):665–667.
21. Haldar S, Jena N, Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995, 92(10):4507–4511.
22. Wiemek PH, Schwartz EL, Stimson JA, Butcher JP, Lipton RB, Phillips J, Von HD: Interim toxicology and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol 2013, 31. doi:10.1200/JCO.2013.120.5511.
23. Liang H-C, Nair S, Yeh I-T, Santillan A, Hu Y, Elledge R, Li R: Association of radiotherapy with preferential depletion of luminal epithelial cells in a BRCA1 mutation carrier. Exp Hematol Oncol 2012, 1(1):31.
24. Incorvati J, Shah S, Mu Y, Lu J: Targeted therapy for HER2 positive breast cancer. J Hematol Oncol 2013, 6:138.
25. Bracini AL, Aziza D, Thezeenas R, Romieu G, Ferrero JM, Jacot W: Prognostic factors of brain metastases from breast cancer: impact of targeted therapies. Breast. doi:10.1016/j.breast.2013.10.011.
26. Rufyath S, Rasul M, Lee B, Wei G, Lamba G, Liu D: Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. J Hematol Oncol 2012, 5:110.
27. Elbaz H, Stueckle T, Tse W, Rojanasakul Y, Dinu C: Digtitoxin and its analogs as novel cancer therapeutics. Exp Hematol Oncol 2012, 1:14.
28. Xu D, Wang Q, Jiang Y, Zhang Y, Vega-SaenzdeMiera E, Osmian I, Dai W: Roles of Poly-like kinase 3 in suppressing tumor angiogenesis. Exp Hematol Oncol 2012, 1:15.
29. Beklemisheva AA, Fang Y, Feng J, Ma X, Dai W, Chao JW: Epigenetic mechanism of growth inhibition induced by phenethylisothiocyanate in prostate cancer cells. Anticancer Res 2006, 26(2A):1225–1230.
30. Wang LG, Liu XM, Fang Y, Dai W, Chao FB, Puccio GM, Feng J, Liu D, Chao JW: De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 2008, 33(2):375–380.
31. Wang LG, Beklemisheva A, Liu XM, Ferrari AC, Feng J, Chao JW: Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer. Mol Carcinog 2007, 46(12):34–38.
32. Cang S, Feng J, Konno S, Han L, Liu K, Sharma SC, Choudhury M, Chao JW: Deficient histone acetylation and excessive deacetylation activity as epigenomeric marks of prostate cancer cells. In: Int J Oncol 2009, 35:1417–1422.
36. Zou Y, Ma X, Huang Y, Hong L, Chiao JW: Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia. J Hematol Oncol 2012, 5(1):36.

37. Liu K, Cang S, Ma Y, Chiao JW: Synergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells. Cancer Cell Int 2013, 13(1):10.

38. Li P, Xiao Z, Hood BL, Dakshanamurthy S, Wang X, Govind S, Conrads TP: Phenethyl isothiocyanate inhibits histone deacetylases and remolds chromatin to induce growth arrest in human leukemia cells. Int J Oncol 2006, 28(5):1287–1293.

39. Wade PA: Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet 2001, 10(7):693–698.

40. Lu Q, Lin X, Feng J, Zhao X, Gallagher R, Lee MY, Chiao JW, Liu D: Phenethyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol 2008, 1(6).

41. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP: HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417(6887):455–458.

42. Lindqvist A, van ZW, Karlsson RC, Wolthuis RM: Cyclin B1-Cdk1 activation continues after centrosome separation to control mitotic progression. PLoS Biol 2007, 5(5):e123.

43. Chantaya G, Alexander J, Babu P: PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal 2010, 8(1):31.

44. Piperno G, Lechat M, Chang XJ: Microtubules containing acetylated alpha-tubulin in mammalian cells in culture. J Cell Biol 1987, 104(2):289–302.

45. Mi L, Xiao Z, Blood BL, Dakshanamurthy S, Wang X, Govind S, Conrads TP, Veenstra TD, Chung FL: Covalent binding to tubulin by isothiocyanates. A mechanism of cell growth arrest and apoptosis. J Biol Chem 2008, 283(32):21136–21146.

46. Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podatz KC, Jiang SW: Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 2006, 5(11):2767–2776.

47. Xiao D, Powolny AA, Mouna MB, Kelley EE, Bommareddy A, Kim SH, Hahm ER, Normolle D, Van Houten B, Singh SV: Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells. J Biol Chem 2010, 285(34):26558–26569.

48. Xiao D, Singh SV: p66Shc is indispensable for phenethyl isothiocyanate-induced apoptosis in human prostate cancer cells. Cancer Res 2010, 70(8):3150–3158.

49. Xiao D, Singh SV: Phenethyl isothiocyanate sensitizes androgen-independent human prostate cancer cells to docetaxel-induced apoptosis in vitro and in vivo. Phar Res 2010, 27(4):722–731.

50. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelciano H, Chiao PJ, Achanta G, Artinghaus RB, Liu J, et al: Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006, 10(3):241–252.

51. Badia E, Oliva J, Balaguer P, Cavailles Y: Tamoxifen resistance and epigenetic modifications in breast cancer cell lines. Curr Med Chem 2007, 14(28):3035–3045.

52. Thomas S, Thum KT, Bicaku E, Marchon DC, Munster PN: Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat 2011, 130(2):437–447.